Italia markets close in 4 hours 39 minutes

FTSE MIB
34.777,43
+285,02(+0,83%)
Dow Jones
38.686,32
+574,82(+1,51%)
Nasdaq
16.735,02
-2,08(-0,01%)
Nikkei 225
38.923,03
+435,13(+1,13%)
Petrolio
76,88
-0,11(-0,14%)
Bitcoin EUR
63.689,34
+1.411,48(+2,27%)

NBIX Dec 2024 105.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

6,75

0,00

(0,00%)

In data: 11:18AM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat